Compositions and methods for nucleic acid delivery to the lung
US5994314A · kind A · utility
46Cited by
2References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 1995 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Apr 14, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/1623
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A dry powder composition comprises insoluble nucleic acid constructs dispersed within with a hydrophilic excipient material, where the powder particles have an average size in the range from 0.5 .mu.m to 50 .mu.m. Nucleic acid constructs may comprise bare nucleic acid molecules, viral vectors, or vesicle structures. The hydrophilic excipient material will be selected to stabilize the nucleic acid molecules in the constructs, enhance dispersion of the nucleic acid in dry powder aerosols, and enhance wetting of the nucleic acid constructs as they are delivered to moist target locations within the body.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.